Opexa restructuring

Opexa reduced headcount by 8 (40%) to 12 after the company's Tcelna imilecleucel-T missed the primary and secondary endpoints in the Phase IIb Abili-T trial to treat secondary progressive multiple sclerosis (SPMS). Tcelna comprises patient-specific myelin reactive T cells (MRTCs) primed and expanded ex vivo with myelin-associated peptides. Chief Development Officer Donna Rill and Scott Seamen, a director, resigned. Earlier this year, Opexa reduced headcount by 28% to complete the trial. The company expects further restructuring by year end...